selective anticoagulation
PreclinicalSmall molecule
selective anticoagulation is one of 10 small molecule programs targeting Thromboembolism. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Thromboembolism
#DrugCompanyPhaseTrials
1Eliquis
Bristol-Myers SquibbApproved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Arixtra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Coumadin
AAbbott
Approved
Pradaxa
Boehringer IngelheimApproved
Coumadin
AAbbott
Preclinical
Tissue Plasminogen Activator
NNeuroscience Trials Australia
Preclinical
Xarelto
BayerPreclinical
selective anticoagulation
GGuangdong Provincial People's Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for selective anticoagulation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details